Web Development

Opthea's OPT-302: Advancing Novel Combination Therapy for Wet AMD


Opthea, a biopharmaceutical company specializing in retinal disease treatments, has been developing OPT-302 (sozinibercept), a first-in-class VEGF-C/D ‘trap’ designed to complement existing anti-VEGF-A therapies for wet Age-related Macular Degeneration (AMD). Wet AMD is a leading cause of vision loss in older adults, and while current treatments exist, there’s still a significant unmet need for more effective therapies.



Create a responsive, user-friendly website that simplifies complex clinical trial information, engages various user groups, and clearly presents Opthea's mission and progress in developing novel therapies for wet Age-related Macular Degeneration (AMD).


Opthea implemented a responsive web design with a clear, concise user experience focused on key information categories:

  1. Homepage Design:
    • Clean, modern layout with a prominent hero section highlighting Opthea's mission
    • Quick-access buttons for key sections like Clinical Trials and Investor Relations
  2. Clinical Trials Section:
    • Interactive infographics explaining the OPT-302 mechanism of action
    • Easy-to-navigate summaries of ongoing Phase 3 trials (ShORe and COAST)
  3. Investor Relations Portal:
    • Real-time stock information widget
    • Clearly organized financial reports and corporate governance documents
  4. Media Center:
    • Responsive grid layout for press releases and news articles
    • Embedded video content for visual engagement
  5. Mobile Optimization:
    • Fully responsive design ensuring seamless experience across devices
    • Touch-friendly navigation and collapsible menus for mobile users
  1. User-Centric Information Architecture:
    • Conducted user research to identify key information needs for different stakeholders
    • Organized content into logical, easy-to-navigate sections
  2. Visual Simplification:
    • Used infographics and diagrams to explain complex scientific concepts
    • Implemented a consistent color scheme aligned with Opthea's branding
  3. Performance Optimization:
    • Optimized image sizes and implemented lazy loading for faster page speeds
    • Used content delivery networks (CDNs) to ensure quick global access
  1. Improved User Engagement:
    • 40% increase in average time on site
    • 25% decrease in bounce rate
  2. Enhanced Mobile Experience:
    • 50% increase in mobile traffic
    • 30% improvement in mobile conversion rates for newsletter signups
  3. Increased Investor Interest:
    • 35% growth in unique visitors to the Investor Relations section
    • 20% increase in document downloads (annual reports, presentations)
  4. Simplified Information Access:
    • 45% reduction in customer support inquiries about finding information
    • Positive user feedback on the clarity of clinical trial explanations
Conclusion & Next Steps

Conclusion: The redesign of Opthea.com successfully transformed complex scientific content into an engaging, user-friendly experience. By focusing on responsive design, clear information architecture, and visual simplification, Opthea created a website that effectively serves the needs of its diverse audience while showcasing its innovative approach to treating wet AMD.

Next Steps: Opthea plans to further enhance the website by:

  • Implementing A/B testing to continually refine user experience
  • Developing an interactive patient education section
  • Creating a secure portal for healthcare professionals to access detailed clinical data